In a ground breaking new development for farmers and for animal welfare – the Australian Veterinarian Medicine regulator (APVMA) has now extended the approved use of Tri-Solfen® anaesthetic and antiseptic topical application to include the alleviation of pain in calves.
Tri-Solfen® is already approved by the APVMA, and widely used in over 8 million lambs per year to alleviate pain from husbandry procedures such as castration, tail docking and mulesing.
Tri-Solfen® has a unique 3-way action designed to numb the wound, minimise bleeding and protect against infection. Scientific trials have demonstrated pain alleviation up to 24 hours in calves after surgical castration and a significant improvement in wound healing in lambs. To date, Over 70 million animals have been treated with Tri-Solfen®, with the product purchased over the counter in Australia from local veterinarians or from rural retailers.
On-going trials conducted by Sydney University Veterinary School and were used to support the registration, confirmed that Tri-Solfen® is highly effective and safe to alleviate pain post castration and disbudding in calves. In addition recent studies conducted by Sydney University have also confirmed a significant reduction in pain associated with piglet castration and these studies will be used to extend the use in piglets in the near future.
It is a major win for farmers, a win for calves, a win for animal welfare – and a win for the Australian cattle and dairy industry says Allan Giffard, Managing Director of Animal Ethics. Tri-Solfen® is now approved to provide a practical means for farmers to alleviate the pain associated with husbandry procedures in calves, which are relied on for important animal health and management reasons. This in turn may improve mothering-up, minimise set-back, while also addressing consumer concerns over welfare.
‘Farm animals experience pain in the same way as dogs, cats and other companion animals. They deserve the same respect and effort to develop safe, affordable and effective pain relief and wound care that is practical for farmers to use. Tri-Solfen® provides the first important product to address this need’.
Allan Giffard concluded “This is a very exciting milestone for our company and the new calf registration sets a solid platform for Animal Ethics as we continue our international registration program in key markets such as the USA, EU, Canada, New Zealand and South America.
– Ends –
About Medical Ethics
Medical Ethics is a commercial and development stage company focused on pain mitigation in wounds for humans and animals.
Through our proven patent protected platform technology, we have identified a transformational way of mitigating pain and minimising suffering associated with wounds.
Tri-Solfen® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen® contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting Bupivacaine for prolonged post-operative pain relief. Adrenaline is included for its ability to reduce the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen® also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.
Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286
Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000